Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Werden Sie kostenlos Mitglied
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON
  1. Startseite
  2. Aktien
  3. Vereinigtes Königreich
  4. London Stock Exchange
  5. ReNeuron Group plc
  6. News
  7. Andere Sprachen
    RENE   GB00BF5G6K95

RENEURON GROUP PLC

(A2JBKZ)
  Bericht
verzögerte Kurse. Verzögert London Stock Exchange - 23.09. 17:35:18
93 GBX   -3.13%
2020RENEURON GROUP PLC : RIGHTS ISSUE: 1 new share @ 0.7 GBP for 9 existing shares
FA
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über RENEURON GROUP PLC
11.08.RENEURON : Annual Report 2021
06.08.London Shares Fall as Investors Await US Jobs Data
06.08.FTSE 100 Edges Lower, BOE Points to Gradual Tightening, Will Lift Pound
06.08.RENEURON : To Appoint New CFO In October
06.08.ReNeuron Group plc Appoints Catherine Isted as Chief Financial Officer Effective 11 Oct..
14.07.ReNeuron Group plc Announces Appointment of Barbara Staehelin as Senior Independent Non..
09.07.RENEURON : Preliminary results presentation for the year ended 31 March 2021
08.07.RENEURON : Preliminary Results for the year ended 31 March 2021
08.07.RENEURON : Earnings Flash (RENE.L) RENEURON GROUP Posts FY21 Revenue GBP257,000
08.07.RENEURON : Earnings Flash (RENE.L) RENEURON GROUP Posts FY21 Loss GBX-29.00
08.07.ReNeuron Group plc Reports Preliminary Earnings Results for the Year Ended March 31, 20..
02.07.RENEURON : Notice of Results
01.07.ReNeuron Group plc Announces Management Changes
09.06.RENEURON : Update for hRPC therapy candidate study
20.05.RENEURON : Appoints New Chief Scientific Officer
20.05.RENEURON : Appointment of Chief Scientific Officer
20.05.ReNeuron Group plc Appoints Stefano Pluchino as Chief Scientific Officer
29.04.RENEURON : Initiation of research by Allenby Capital
06.04.RENEURON : Virtual conference attendance and presentations
19.03.RENEURON : Exosome platform update
12.03.RENEURON : CFO Steps Down
12.03.RENEURON : Directorate Change
12.03.Reneuron Group plc Announces Resignation of Michael Hunt, Executive Director
12.03.ReNeuron Group plc Announces Resignation of Michael Hunt, Chief Financial Officer
26.02.RENEURON : Appointment of Joint Broker
26.02.RENEURON : Investor presentations
25.02.RENEURON : Appointment of Joint Broker
25.02.RENEURON : Investor presentations
18.01.RENEURON : Clinical update
15.01.European Stocks Decline Friday After Some EU Member States Complain of Low Supply of CO..
15.01.RENEURON : Doses First Group of Patients in Trial for Eye Disease Treatment; Shares Up 13%
15.01.RENEURON : Clinical Update
06.01.RENEURON : Investor Presentation – 6 January 2021
06.01.RENEURON : Analyst Conference Call
2020RENEURON : Notification of Allowance granted for US patent
2020RENEURON : Result of Open Offer
2020European Stocks Retreat Friday on Uncertain Post-Brexit Trade Deal, US Stimulus Package
2020RENEURON : Shares Jump 8% On $23.1 Million Share Placement
2020RENEURON : Result of Open Offer
2020RENEURON : Interim Statement 2020
2020RENEURON : Result of Placing and Subscription, PDMR Dealings and Notice of General Meeting
2020RENEURON : Interim Results for the six months ended 30 September 2020
2020RENEURON : Proposed Placing, Subscription and Open Offer
2020RENEURON : Sinks 18% Amid Plan to Raise $20.1 Million to Fund Two R&D Programs
2020RENEURON : Plunges 18% On Bigger H1 Loss
2020RENEURON : Result of Placing and Subscription, PDMR Dealings and Notice of General Meeting
2020RENEURON : Interim Results for the six months ended 30 September 2020
2020RENEURON : Result of Placing and Subscription and GM Notice
2020RENEURON : Earnings Flash (RENE.L) RENEURON GROUP Posts H1 Revenue GBP41,000
2020RENEURON : Earnings Flash (RENE.L) RENEURON GROUP Reports H1 EPS GBX-22.3
2020ReNeuron Group plc Announces Unaudited Consolidated Earnings Results for the Six Months..
2020RENEURON : Proposed Placing, Subscription and Open Offer
2020Reneuron Group plc Announces Unaudited Consolidated Financial Results for the Six Month..
2020Reneuron Group plc Reports Patient Dosing Now Commenced in the US in the Expanded Phase..
2020RENEURON : Posting of Annual Report and Accounts and Notice of AGM
2020ReNeuron Group plc Auditor Raises 'Going Concern' Doubt
2020Reneuron Group plc Announces Changes to Non-Executive Membership of the Board, Effectiv..
2020RENEURON : Notification of Allowance granted for US patent
2020RENEURON : Notification of Allowance granted for US Patent
2020RENEURON GROUP PLC COMPLETES EXAMINA : Phenotype Profile of Human Retinal Progenitor Cells
2020RENEURON : Preliminary Results for the year ended 31 March 2020
2020RENEURON : 2020 Preliminary Results Presentation
2020RENEURON : Preliminary Results for the year ended 31 March 2020
2020ReNeuron Group plc Announces Audited Earnings Results for the Year Ended March 31, 2020
2020RENEURON : Further positive data in retinal clinical trial
2020ReNeuron Group plc Announces Further Positive Data in Retinal Clinical Trial
2020RENEURON : Further Positive Data in Retinal Clinical Trial
2020RENEURON : ReNeuron signs new exosome research collaboration
2020ReNeuron Signs New Exosome Research Collaboration
2020RENEURON : signs new exosome research collaboration
2020RENEURON : New Exosome Research Collaboration
2020RENEURON : Regulatory approvals and programme update
2020ReNeuron Group plc Provides Program and Regulatory Approvals Update
2020RENEURON : Regulatory Approvals and Programme Update
2020ReNeuron Announces CTX Cell Line Shows Further Potential
1  2Weiter